SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

Read more breaking news

 

 

iBio licences plant-based tech for H1N1 vaccine production

By Nick Taylor , 01-Mar-2010

iBio has agreed in principle to license its iBioLaunch platform, which uses Nicotiana to produce therapeutics, to G-Con for the development and manufacture of plant-expressed influenza vaccines.

Plant-based production has been proposed as a rapid response, low cost alternative with the ability to massively scale up. G-Con’s GreenVax Project intends to show proof-of-concept for a large-scale vaccine production facility using Nicotiana plants grown in a controlled environment.

The project will initially look at producing H1N1 vaccines. iBio believes its platform is particularly suited to producing vaccines in response to pandemics because of the speed advantages it offers over egg-based manufacture.

Non-genetically-modified plants used in iBioLaunch have short growing cycles and this, coupled to the transient nature of the gene expression technology, helps cut the time from isolating the strain to production.

When manufacture begins it can be quickly scaled-up by simply growing more plants in the contained growth facilities. G-Con will perform this process on a secure, 21-acre site at the Texas A&M Health Science Center in Bryan, Texas, US.

A 145,000 sq ft bio-production facility capable of producing 100m doses a month is being constructed at the site. The facility has been designed to complete the GreenVax Project but can be expanded without interrupting core operations.

H1N1 is the target of the GreenVax Project but iBioLaunch can be applied to seasonal influenza, other infectious diseases or cancer. Robert Kay, CEO of iBio, expects “influenza, including seasonal influenza, to be among the earliest applications of the iBioLaunch technology”.

He added: “In the new GreenVax facility, G-Con’s modular production technology should significantly enhance the economy, speed and flexibility advantages of our system for application to a broad range of biologic products.”

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions